Slides
Page 1
Turning Strategy into Results Jean-Christophe Tellier, CEO 44th Annual J.P. Morgan Healthcare Conference January 14th, 2026
Page 2
2 Proprietary Property of UCB UCB – 44th Annual J.P. Morgan Healthcare Conference | 14th January 2026 Disclaimer & Safe Harbor This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document. Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB’s information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems. Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB. UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.
Page 3
Proprietary and Confidential Property of UCBProprietary and Confidential Property of UCB 3 Proprietary and Confidential Property of UCB Performance Driven by Strength
Page 4
4 Proprietary Property of UCB UCB – 44th Annual J.P. Morgan Healthcare Conference | 14th January 2026 *As of December 2024. UCB Integrated Annual Report 2024; ** Patent protection in the U.S.. Bimzelx® date assumes patent term extension is granted. Strong Growth Engine Built on Innovation Strong Foundation 5 Growth Drivers Patent Protection** Est. Global biopharma company Legacy of scientific excellence Sustainability as business approach Listed on Euronext Brussels ImmunologyNeurology >3.1 M patients accessed our solutions* Present in 36 countries* ~9,300 employees* R&D spend 29% of revenue* 2037 First and only IL-17A & IL-17F inhibitor 2035 First agent for anti-AChR+ & anti-MuSK+ gMG First and only once-daily subcutaneous C5 inhibitor 2035 2033 Foundational therapy in DS, a recognized option in LGS 2033 Only sclerostin-inhibitor & leader in Bone-Builder Patent Protection Patent Protection Patent Protection Patent Protection
Page 5
5 Proprietary Property of UCB UCB – 44th Annual J.P. Morgan Healthcare Conference | 14th January 2026 Agility and Resilience Supporting Growth Continuous investment in differentiated innovation and patient biology Biomanufacturing expansion to support current portfolio and future pipeline Inorganic growth as integrated part of our strategy Investment in diverse platforms & modalities ~$5bn U.S. investment in mammalian antibody plant; BIMZELX® in-house manufacturing launch Strategic flexibility supporting proactive long-term planning
Page 6
6 Proprietary Property of UCB UCB – 44th Annual J.P. Morgan Healthcare Conference | 14th January 2026 2025 Outlook Upgraded on Sustained Momentum *Excludes the benefit from a sale of established brands; LOE : Loss of Exclusivity. Disciplined execution to sustain long-term growth, while absorbing the impact of BRIVIACT ® LOE and net pricing dynamics in 2026 Powered by the five growth drivers, with BIMZELX® exceeding expectations through strong demand and favorable U.S. payer mix adjusted EBITDA MarginAnnual Revenue €6.15bn >€7.6bn 24% >31%* 2024 Actual 2025 Projected 2024 Actual 2025 Projected >24% >700 bps 2026 Financial Guidance at Constant Exchange Rate, to be provided on 26 February 2026
Page 7
Proprietary and Confidential Property of UCBProprietary and Confidential Property of UCB 7 Proprietary and Confidential Property of UCB Strategy in Action
Page 8
8 Proprietary Property of UCB UCB – 44th Annual J.P. Morgan Healthcare Conference | 14th January 2026 Focused Innovation & Scientific Excellence Patient-Centric Approach Anchored in Disease Biology Scaling Impact Through Execution Excellence UCB’s Long-term Value Creation
Page 9
9 Proprietary Property of UCB UCB – 44th Annual J.P. Morgan Healthcare Conference | 14th January 2026 Differentiated Innovation in Action * In the U.S.. ** An ultra-rare debilitating and life-threatening (often fatal) genetic mitochondrial disease estimated to affect approximately 2,000 patients globally Thymidine Kinase 2 deficiency** first and only approved* treatment for adult and pediatric patients US 550 EU5 530 RoW 450 Strong ecosystem partnerships with approvals supported by real-world evidence alongside pivotal trials Deep disease-biology insight targeting high unmet need Agile commercial execution leveraging partnerships Estimated Number of Patients
Page 10
10 Proprietary Property of UCB UCB – 44th Annual J.P. Morgan Healthcare Conference | 14th January 2026 AD = Atopic Dermatitis;1. Langan SM, Irvine AD and Weidinger S. Lancet. 2020;396:345-360; 2. Stanyon S et al. Poster presented at ESDR 2025; September 10–13, 2025; Antwerp, Belgium. Poster 20; Th=T helper cell first and only IL-13 and IL-17A & IL-17F inhibitor Mechanism of AD pathogenesis1,# Encouraging 12-week skin- clearance with an acceptable risk- benefit profile, supporting differentiated potential Multispecific antibody addressing disease heterogeneity beyond Th2 biology PHASE 2B ONGOING: Defining optimal dosing and broadening the disease opportunity beyond AD Differentiated Innovation in Action
Page 11
11 Proprietary Property of UCB Targeting pathological tau to transform the treatment of early Alzheimer's disease Bepranemab is the first-ever tau antibody to slow clinical decline, with a well tolerated safety Tau is the next frontier in Alzheimer’s disease with disease care shifting to earlier intervention and biology-led treatment Bepranemab’s robust benefit in low-tau early disease in the TOGETHER Phase 2 trial paves a clear development path forward, with the potential to benefit millions of patients Differentiated Innovation in Action Slowing of neurodegeneration and disease progression Bepranemab binds to extracellular tau aggregates in the brain1–3 Neurofibrillar y tangles Tau aggregates Sources: 1. Yanamadra, et al., Neuron. 2013;80(2):402-414; 2. Courade et al. Acta Neuropathol. 2018; 136: 729–745; 3. Albert M et al. Brain. 2019;142: 1736–1750. UCB – 44th Annual J.P. Morgan Healthcare Conference | 14th January 2026
Page 12
12 Proprietary Property of UCB UCB – 44th Annual J.P. Morgan Healthcare Conference | 14th January 2026 approved in 50 countries …by 21 Regulatory Authorities …across 5 indications bimekizumab indication expansion • Pediatric (PSO, HS, JIA) • Palmoplantar Pustulosis (PPP) Execution Excellence in Action PSO = Psoriasis; HS = hidradenitis suppurativa; JIA = Juvenile idiopathic arthritis; PPP = palmoplantar pustulosis *EC approval extends to European Economic Area (EEA) countries of Iceland, Liechtenstein and Norway. 320mg dose / 2mL device approved in EU, GB, US, CA, JP, AUS, BR, and CH. Bimekizumab label information may differ across countries. Please check local prescribing information for additional guidance.
Page 13
13 Proprietary Property of UCB UCB – 44th Annual J.P. Morgan Healthcare Conference | 14th January 2026 Total BIMZELX Patients (R3M)* BIMZELX Strategic Access Expansion 2026 M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 M14 M15 M16 M17 M18 M19 M20 M21 M22 M23 M24 M25 M26 BIMZELX Cosentyx Taltz Skyrizi Tremfya Patient adoption outpacing analogues – all indications Execution Excellence in Action * R3M = Rolling 3 months, source IQVIA; ** All indications at 1st Line or DSE. Includes access expansion in both the commercial and the Medicare Part D channels, with the majority of these additional lives in the commercial channel. M= million; IL = Interleukin; DSE = Double Step Edit ≥80% & vast majority of Medicare & Medicaid patients +36M** 25% increase vs. 2025
Page 14
14 Proprietary Property of UCB UCB – 44th Annual J.P. Morgan Healthcare Conference | 14th January 2026 Execution Excellence in Action >1.2M patients Most Recent approval in China (December 2025) Approved by 12 regulatory authorities Robust, Consistent, Flexible Approved by 10 regulatory authorities Potent, Sustained, Empowered Positive Phase 3 in CDKL5 Deficiency Disorder as 3rd DEE Addition of RETT, expanding our reach beyond epilepsy M = million; DDE = developmental and epileptic encephalopathy
Page 15
15 Proprietary Property of UCB Executing with agility and resilience to deliver future solutions for patients, this decade and beyond A position of Strength … Driving Growth for a Decade+ UCB – 44th Annual J.P. Morgan Healthcare Conference | 14th January 2026 Purpose-led performance, creating long-term value for patients, shareholders, employees, and the planet Differentiated innovation translating science into new and targeted therapies
Page 16
Proprietary and Confidential Property of UCB